BioSpace News Archive

Increasing adoption of FFR-CT among the healthcare professional is expected to drive the market through 2030

According to the report, the global disposable syringes market was valued at US$ 6.9 Bn in 2019 and is expected to expand at a CAGR of ~7% during the forecast period from 2020 to 2030.

The management of neonatal jaundice amidst the COVID-19 pandemic has posed unique challenges for healthcare professionals.

Telemedicine consultations are being highly publicized for the management of dry eye disease amidst the coronavirus pandemic.

With the tremendous rise in the prevalence of cancer across the world, the global market for cancer diagnostics is witnessing a remarkable surge in its size.

Preliminary Clinical Activity Shown, With Tumor Regression in 4 of 5 TKI-Naïve Patients Including 2 Confirmed Partial Responses Preliminary Clinical Activity Shown, With Tumor Regression in 3 of 9 TKI-Pretreated Patients Across 6 Dose Finding Cohorts, Generally Well Tolerated Preliminary Safety Profile Continued Dose Finding with Phase 1 Dose Expansion Planned Conference Call Scheduled for 4:30 p.m. Eastern Time

Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company’s board of directors, effective April 1, 2021. Dr. Owens will serve as a member of the Compensation Committee.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer.

Encouraging results from a study of its MosaiQ™ multiplex molecular disease screening (MDS) Microarray MDS product progressing through development Update regarding progress on the Company’s MosaiQ expanded Immunohematology (IH) microarray Commercial launch of Expanded IH together with already CE marked Initial SDS on track to be launched in Europe around year-end 2021

Pharmacodynamic study will compare OPNT003, nasal nalmefene, with nasal naloxone in reversing the respiratory depression produced by the synthetic opioid, remifentanil Top-line data expected in the fourth quarter This trial starts at a time when deaths resulting from opioid overdose are at record highs